JP2017522300A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522300A5
JP2017522300A5 JP2016575499A JP2016575499A JP2017522300A5 JP 2017522300 A5 JP2017522300 A5 JP 2017522300A5 JP 2016575499 A JP2016575499 A JP 2016575499A JP 2016575499 A JP2016575499 A JP 2016575499A JP 2017522300 A5 JP2017522300 A5 JP 2017522300A5
Authority
JP
Japan
Prior art keywords
dihydro
benzoxazin
oxo
carbonyl
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016575499A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522300A (ja
JP6368383B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2015/051860 external-priority patent/WO2016001631A1/en
Publication of JP2017522300A publication Critical patent/JP2017522300A/ja
Publication of JP2017522300A5 publication Critical patent/JP2017522300A5/ja
Application granted granted Critical
Publication of JP6368383B2 publication Critical patent/JP6368383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016575499A 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド Active JP6368383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462018790P 2014-06-30 2014-06-30
US62/018,790 2014-06-30
PCT/GB2015/051860 WO2016001631A1 (en) 2014-06-30 2015-06-26 Benzoxazinone amides as mineralocorticoid receptor modulators

Publications (3)

Publication Number Publication Date
JP2017522300A JP2017522300A (ja) 2017-08-10
JP2017522300A5 true JP2017522300A5 (enExample) 2018-07-19
JP6368383B2 JP6368383B2 (ja) 2018-08-01

Family

ID=53539739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575499A Active JP6368383B2 (ja) 2014-06-30 2015-06-26 鉱質コルチコイド受容体修飾因子としてのベンゾオキサジノンアミド

Country Status (26)

Country Link
US (2) US10017502B2 (enExample)
EP (1) EP3160948B1 (enExample)
JP (1) JP6368383B2 (enExample)
KR (1) KR102012222B1 (enExample)
CN (1) CN106536491B (enExample)
AR (1) AR101036A1 (enExample)
AU (1) AU2015282450C1 (enExample)
CA (1) CA2953655C (enExample)
CY (1) CY1121596T1 (enExample)
DK (1) DK3160948T3 (enExample)
EA (1) EA029518B1 (enExample)
ES (1) ES2707726T3 (enExample)
HR (1) HRP20190147T1 (enExample)
HU (1) HUE042370T2 (enExample)
LT (1) LT3160948T (enExample)
ME (1) ME03316B (enExample)
MX (1) MX367404B (enExample)
PL (1) PL3160948T3 (enExample)
PT (1) PT3160948T (enExample)
RS (1) RS58274B1 (enExample)
SI (1) SI3160948T1 (enExample)
SM (1) SMT201900039T1 (enExample)
TR (1) TR201900659T4 (enExample)
TW (1) TWI677498B (enExample)
UY (1) UY36195A (enExample)
WO (1) WO2016001631A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201900659T4 (tr) * 2014-06-30 2019-02-21 Astrazeneca Ab Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
MY210508A (en) 2018-07-19 2025-09-28 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
CN112107568B (zh) * 2019-06-19 2022-03-25 北京龙嘉博创医药科技有限公司 二芳基酰胺类化合物及其应用
PE20211267A1 (es) * 2019-08-30 2021-07-19 Astrazeneca Ab Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina
EP4188389B1 (en) 2020-07-27 2025-09-17 AstraZeneca AB Dapagliflozin for use in methods of treating chronic kidney disease
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4357336A4 (en) * 2021-06-15 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co Ltd BENZOXAZINONE DERIVATIVES
TW202409023A (zh) 2022-07-14 2024-03-01 美商富曼西公司 除草苯并𠯤
JP2025527854A (ja) 2022-09-01 2025-08-22 アストラゼネカ・アクチエボラーグ 心腎疾患の治療に使用するためのsglt2阻害剤と鉱質コルチコイド受容体調節剤との組み合わせ
CN120344508A (zh) * 2022-12-15 2025-07-18 正大天晴药业集团股份有限公司 苯并恶嗪酮类化合物的结晶及其制备
WO2025111184A1 (en) 2023-11-21 2025-05-30 Fmc Corporation Substituted tetrahydroquinoline and tetrahydroquinoxaline herbicides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951855B2 (en) * 2001-04-23 2005-10-04 Astrazeneca Ab Benzoxazinone derivatives for use in the treatment of angiogenesis
BR0317572A (pt) * 2002-12-20 2005-11-22 Warner Lambert Co Benzoxazinas e seus derivados como inibidores de pi3ks
WO2006019716A1 (en) * 2004-07-14 2006-02-23 Ligand Pharmaceuticals, Inc. Intracellular receptor modulator compounds and methods
BRPI0512674A (pt) * 2004-07-28 2007-09-25 Irm Llc compostos e composições como moduladores de receptores nucleares de hormÈnio esteróide
WO2007077961A2 (en) 2005-12-28 2007-07-12 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds and their use as mineralocorticoid receptor ligands
TWI385161B (zh) 2006-02-02 2013-02-11 Mitsubishi Tanabe Pharma Corp 含氮雜雙環化合物
BRPI0717937A2 (pt) 2006-10-31 2013-12-03 Pfizer Prod Inc Compostos de pirazona como antagonistas do receptor mineralocorticóide
DE102007009494A1 (de) 2007-02-27 2008-08-28 Bayer Healthcare Ag Substituierte 4-Aryl-1, 4-dihydro-1,6-naphthyridinamide und ihre Verwendung
WO2008118319A2 (en) 2007-03-23 2008-10-02 Merck & Co., Inc. Mineralocorticoid receptor modulators
DK2133330T3 (da) 2007-04-09 2014-03-31 Daiichi Sankyo Co Ltd Atropisomer af pyrrolderivat
US8258131B2 (en) 2007-08-01 2012-09-04 Mitsubishi Tanabe Pharma Corporation Fused bicyclic compound
JP5173653B2 (ja) * 2007-08-01 2013-04-03 田辺三菱製薬株式会社 医薬組成物
PE20091057A1 (es) 2007-12-19 2009-07-20 Lilly Co Eli Antagonistas del receptor mineralcorticoide y metodos de uso
KR20110017456A (ko) * 2008-06-18 2011-02-21 아스트라제네카 아베 호흡기 장애의 치료를 위한 베타2-아드레날린성 수용체 효능제로서 작용하는 벤족사지논 유도체
US20100094000A1 (en) 2008-09-03 2010-04-15 Takeda Pharmaceutical Company Limited Pyrazole compounds
WO2010098286A1 (ja) 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
MX2011009506A (es) 2009-03-12 2011-09-28 Lilly Co Eli Antagonista del receptor mineralcorticoide y metodos de uso.
US20120022058A1 (en) 2009-04-10 2012-01-26 Pfizer Inc. 4,5-dihydro-1h-pyrazole compounds and their pharmaceutical uses
CN102906495B (zh) 2010-05-11 2016-08-24 皇家飞利浦电子股份有限公司 照明模块
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
WO2012064631A1 (en) 2010-11-10 2012-05-18 Boehringer Ingelheim International Gmbh Pyridyl ureas as mineralocorticoid receptor antagonists
TR201900659T4 (tr) * 2014-06-30 2019-02-21 Astrazeneca Ab Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.

Similar Documents

Publication Publication Date Title
JP2017522300A5 (enExample)
JP2018021046A5 (enExample)
JP2016106149A5 (enExample)
JP2013543896A5 (enExample)
JP2016522254A5 (enExample)
JP2020512337A5 (enExample)
JP2016534063A5 (enExample)
JP2016505637A5 (enExample)
JP2014521735A5 (enExample)
JP2014511892A5 (enExample)
JP2014511891A5 (enExample)
EP4616908A3 (en) Oxysterols and methods of use thereof
JP2016034978A5 (enExample)
JP2018513107A5 (enExample)
JP2016528301A5 (enExample)
JP2012255002A5 (enExample)
JP2016510326A5 (enExample)
JP2016027060A5 (enExample)
JP2017508817A5 (enExample)
JP2015510916A5 (enExample)
JP2014505107A5 (enExample)
JP2014511374A5 (enExample)
JP2015521156A5 (enExample)
JP2012524092A5 (enExample)
JP2019535760A5 (ja) ガボキサドールを用いた注意欠陥多動性障害(adhd)の治療方法